top of page

New Treatment Modality for Epilepsy

  • Writer: anwilner
    anwilner
  • Jul 13, 2019
  • 1 min read

I've been following the development of intranasal therapy of epilepsy for quite a few years. Finally, intranasal midazolam (Nayzilam) has received FDA approval for the treatment of cluster seizures (acute repetitive seizures) on May 20, 2019.


At this year's American Academy of Neurology meeting in Philadelphia, PA, I interviewed Ed Hogan, MD, who presented his research on intranasal diazepam for epilepsy. This preparation also looks promising for FDA approval.


Intranasal therapy for epilepsy is intended as an adjunct to daily medication, so it doesn't remove the daily burden of anti-seizure medication. However, the acute administration of an effective intranasal product may eliminate the need for some costly and inconvenient ER visits, which should help improve the quality of life for patients with uncontrolled cluster seizures.


Please check out my interview with Dr. Hogan here.

 
 
 

Comments


        Ask a question!                                      For  media inquiries,

                                    please contact the author:

Thanks! Message sent.

Disclaimer: The author's website and books do not intend to provide professional business, medical, or legal advice and should not replace the counsel of an accountant, physician, or attorney, repsectively. Although the information has been carefully researched, the author assumes no liability for loss or damages resulting from its use.

 

Books and other products may have affiliate links. "As an Amazon Associate, I earn from qualifying purchases." (It's not much.) The price to you is the same.

Copywrite: Andrew Wilner, MD 2019.

bottom of page